Tetraphase Pharma Decides to Reap Profits With Secondary Offering
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Tetraphase Pharmaceuticals Inc. (NASDAQ: TTPH) saw its shares pull back on Friday after the company announced that it has priced a secondary offering. Keep in mind that even though shares are pulling back from this current price level, the stock is up roughly 70% year to date.
Under the terms of the offering, the firm is selling 10 million shares for $6.50 apiece, with an overallotment option for an additional 1.5 million shares. At this price, the entire offering is valued up to $74.75 million. Tetraphase has a market cap of about $300 million.
The underwriters for the offering are Piper Jaffray, BMO Capital Markets, Stifel, SunTrust Robinson Humphrey and H.C. Wainwright.
This clinical-stage biopharmaceutical company uses its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant (MDR) infections. Tetraphase is developing its lead product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of MDR infections, including Gram-negative infections. The firm is also pursuing the discovery and development of additional antibiotics that target unmet medical needs, including MDR Gram-negative bacteria.
Shares of Tetraphase traded down 7.7%% at $6.42 Friday morning, with a consensus analyst price target of $16.33 and a 52-week range of $3.11 to $9.93.
Contact [email protected] for any questions or corrections.


